Guo Y, Hu J, Wang Y, Peng X, Min J, Wang J, Matthaiou E, Cheng Y, Sun K, Tong X, Fan Y, Zhang PJ, Kandalaft LE, Irving M, Coukos G, Li C (2018) Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma. Eur J Cancer 90:111-121. doi: 10.1016/j.ejca.2017.10.035. PMID: 29304474
Objective: Using Saporin conjugated to 78Fc, an antibody fragment directed towards endosialin a.k.a. CD248, in the treatment of human sarcomas.
Summary: Endosialin/CD248 is over-expressed in human sarcomas, and a human single-chain variable fragment -Fc fusion protein was created targeting CD248. 78Fc-SAP eliminated CD248+ cells without off-target toxicity in vivo in mice and in vitro in human sarcoma cells.
Usage: In vivo: Mice were inoculated with osteosarcoma cells. These mice received, in PBS, either 4 ug of 78Fc-SAP, 1.4 ug of free saporin [PR-01], or no drug. In vitro: At 2.2 nM nearly 100% of CD248+ human sarcoma cell lines ( SJSA-1, A673, MES-SA and HOS) were eliminated. At the same concentration with free saporin ~20% of cells were eliminated.
Related Products: Saporin (Cat. #PR-01)